Apollomics Advances Phase I/II SPARTA Trial for C-MET Inhibitor in MET-Altered Tumors

May 21, 2020

|

NEW YORK – Apollomics has launched the Phase II portion of the Phase I/II SPARTA trial for its investigational c-MET inhibitor APL-101, which will enroll patients with different tumors and MET alterations.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Menu

Apollomics Advances Phase I/II SPARTA Trial for C-MET Inhibitor in MET-Altered Tumors

To read the full story....

Breaking News

Invivoscribe Receives Supplemental Approval for AML Kit

Apollomics Advances Phase I/II SPARTA Trial for C-MET Inhibitor in MET-Altered Tumors

Genentech's Tecentriq Receives First-Line FDA Approval for High PD-L1-Expressing Lung Cancer

AstraZeneca, Daiichi Sankyo's Enhertu Gets FDA Breakthrough Status in HER2-Mutated Lung Cancer

Roche's Flatiron Health, Foundation Medicine, Genentech Launch Clinico-Genomic Lung Cancer Study

Agilent PD-L1 Assay Gets FDA Approval as Metastatic NSCLC Companion Diagnostic

Featured White Papers

Identifying Molecular Drivers of Cancer via Comprehensive Sequencing of a Large Cohort with Matched Germline and Clinical Data

What's Popular?

Janssen Antibody Produces Durable Responses in Lung Cancer Subset With Poor Prognosis

Opdivo, Yervoy Another First-Line Option in NSCLC, Though Maybe Not Some Oncologists' Top Choice

FDA Approves Lynparza With Myriad, Foundation Med CDx Tests in HRR-Mutated Prostate Cancer

Roche's Flatiron Health, Foundation Medicine, Genentech Launch Clinico-Genomic Lung Cancer Study

Q&A: ACMG Work Group Hoping to Spark Discussion on Reporting Germline Findings From Tumor Testing

Sponsorships